Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Long G Wang & Luxi Wang. (2022) Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. ImmunoTargets and Therapy 11, pages 23-35.
Read now
Read now
Yifan Zhou, Xiao Liu, Youzhi Zhang, Long Peng & John Z. H. Zhang. (2018) Residue-specific free energy analysis in ligand bindings to JAK2. Molecular Physics 116:19-20, pages 2633-2641.
Read now
Read now
Tariq I Mughal, Kris Vaddi, Nicholas J Sarlis & Srdan Verstovsek. (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine 7, pages 89-101.
Read now
Read now
Peter Norman. (2014) Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opinion on Investigational Drugs 23:8, pages 1067-1077.
Read now
Read now
Articles from other publishers (24)
Yifat Koren Carmi, Hazem Khamaisi, Rina Adawi, Eden Noyman, Jacob Gopas & Jamal Mahajna. (2023) Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells. International Journal of Molecular Sciences 24:9, pages 7730.
Crossref
Crossref
Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi & Mohammad Hossein Nicknam. (2021) Baricitinib: From Rheumatoid Arthritis to COVID‐19. The Journal of Clinical Pharmacology 61:10, pages 1274-1285.
Crossref
Crossref
Adriana Coricello, Francesco Mesiti, Antonio Lupia, Annalisa Maruca & Stefano Alcaro. (2020) Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 25:15, pages 3321.
Crossref
Crossref
H. Christian Eberl, Thilo Werner, Friedrich B. Reinhard, Stephanie Lehmann, Douglas Thomson, Peiling Chen, Cunyu Zhang, Christina Rau, Marcel Muelbaier, Gerard Drewes, David Drewry & Marcus Bantscheff. (2019) Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. Scientific Reports 9:1.
Crossref
Crossref
Yue Wang, Wenjing Zang, Shiyu Ji, Jinping Cao & Chongde Sun. (2019) Three Polymethoxyflavones Purified from Ougan (Citrus reticulata Cv. Suavissima) Inhibited LPS-Induced NO Elevation in the Neuroglia BV-2 Cell Line via the JAK2/STAT3 Pathway. Nutrients 11:4, pages 791.
Crossref
Crossref
Thilo J. Heckrodt, Yan Chen & Rajinder Singh. (2019) Synthesis of the isotopically labeled JAK1/3 inhibitor [D]-R545 and its oxidative metabolite [D]-R935: Protecting group-directed regioselective bromination to access 3,4,5-substituted anilines. Tetrahedron 75:16, pages 2385-2399.
Crossref
Crossref
Sébastien A. Felt, Gaith N. Droby & Valery Z. Grdzelishvili. (2017) Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus. Journal of Virology 91:16.
Crossref
Crossref
Kyoung Bin Yoon, Sung Yun Cho, Su Jin An, Kyeong Ryang Park, Hyo Jeong Lee, Hae Sung Yoon, Sun-Mi Lee, Yong-Chul Kim & Sun-Young Han. (2017) Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor. Oncology Letters 14:2, pages 1347-1354.
Crossref
Crossref
Wiktoria Blaszczak, Wojciech Barczak, Anna Wegner, Wojciech Golusinski & Wiktoria Maria Suchorska. (2017) Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. Medical Oncology 34:4.
Crossref
Crossref
Chunjie Yu, Qiong Yang, Yuhong Chen, Demin Wang, Ross Levine, John Crispino, Qiang Wen & Zan Huang. (2016) Tyrosine 625 plays a key role and cooperates with tyrosine 630 in MPL W515L-induced signaling and myeloproliferative neoplasms. Cell & Bioscience 6:1.
Crossref
Crossref
Li Li, Lori J. Silveira, Nabeel Hamzeh, May Gillespie, Peggy M. Mroz, Annyce S. Mayer, Tasha E. Fingerlin & Lisa A. Maier. (2016) Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis. European Respiratory Journal 47:6, pages 1797-1808.
Crossref
Crossref
Masaru JinushiSoh YamamotoNoriko OgasawaraHideki NaganoShin HashimotoHiroyuki TsutsumiTetsuo HimiShin-ichi Yokota. (2016) Measles Virus Genotype D Wild Strains Suppress Interferon-Stimulated Gene Expression More Potently than Laboratory Strains in SiHa Cells. Viral Immunology 29:5, pages 296-306.
Crossref
Crossref
Moaz M. Choudhary, Thomas J. France, Theodoros N. Teknos & Pawan Kumar. (2016) Interleukin‐6 role in head and neck squamous cell carcinoma progression. World Journal of Otorhinolaryngology - Head and Neck Surgery 2:2, pages 90-97.
Crossref
Crossref
Vladimir Simov, Sujal V. Deshmukh, Christopher J. Dinsmore, Fiona Elwood, Rafael B. Fernandez, Yudith Garcia, Craig Gibeau, Hakan Gunaydin, Joon Jung, Jason D. Katz, Brian Kraybill, Blair Lapointe, Sangita B. Patel, Tony Siu, Hua Su & Jonathan R. Young. (2016) Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 26:7, pages 1803-1808.
Crossref
Crossref
Rupali DasPeng GuanLeslee SpragueKatherine Verbist, Paige Tedrick, Qi Angel AnCheng ChengMakoto KurachiRoss Levine, E. John WherryScott W. Canna, Edward M. Behrens & Kim E. Nichols. (2016) Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127:13, pages 1666-1675.
Crossref
Crossref
Meili ZhangLesley A. Mathews GrinerWei JuDamien Y. DuveauRajarshi GuhaMichael N. PetrusBernard WenMichiyuki MaedaPaul ShinnMarc FerrerKevin D. ConlonRichard N. BamfordJohn J. O’Shea, Craig J. ThomasThomas A. Waldmann. (2015) Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2–dependent adult T-cell leukemia. Proceedings of the National Academy of Sciences 112:40, pages 12480-12485.
Crossref
Crossref
Marzena Ciechomska, Jacob van Laar & Steven O'Reilly. (2015) Current frontiers in systemic sclerosis pathogenesis. Experimental Dermatology 24:6, pages 401-406.
Crossref
Crossref
Ali Saber, Anthonie van der Wekken, Thijo J.N. Hiltermann, Klaas Kok, Anke van den Berg & Harry J.M. Groen. (2015) Genomic aberrations guiding treatment of non-small cell lung cancer patients. Cancer Treatment Communications 4, pages 23-33.
Crossref
Crossref
Claire E. Stewart, Richard E. Randall & Catherine S. Adamson. (2014) Inhibitors of the Interferon Response Enhance Virus Replication In Vitro. PLoS ONE 9:11, pages e112014.
Crossref
Crossref
James D. Clark, Mark E. Flanagan & Jean-Baptiste Telliez. (2014) Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases. Journal of Medicinal Chemistry 57:12, pages 5023-5038.
Crossref
Crossref
Neil Gildener-Leapman, Robert L. Ferris & Julie E. Bauman. (2013) Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncology 49:12, pages 1089-1096.
Crossref
Crossref
Brigitte C. WidemannJaishri O. BlakeleyEva DombiMichael J. FisherClemens O. HanemannKarin S. WalshPamela L. WoltersScott R. Plotkin. (2013) Conclusions and future directions for the REiNS International Collaboration. Neurology 81:21_supplement_1.
Crossref
Crossref
D Escobar-Zarate, Y-P Liu, L Suksanpaisan, S J Russell & K-W Peng. (2013) Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Therapy 20:10, pages 582-589.
Crossref
Crossref
. (2013) Organische Chemie 2012. Nachrichten aus der Chemie 61:3, pages 265-297.
Crossref
Crossref